title: [Effects of clinically effective dose of lovastatin on prostate cancer PC3 cells].
abstract: OBJECTIVE
  To investigate the effects of clinically achievable dose of lovastatin on prostate cancer PC3 cells.
  
  
  METHODS
  PC3 prostate cancer cells were treated with dimethyl sulfoxide(DMSO),or lovastain only,or lovastatin with mevalonic acid for 24, 48 and 72 hours respectively. MTT assay was used to detect the cell viability. By means of [3H] thymidine incorporation tests, the effects of lovastatin on cell proliferation were analyzed. Western blot was used to detect activated casepase3, caspase7, and cleaved PARP (cPARP), the important molecules on the apoptosis pathway.
  
  
  RESULTS
  Cell proliferation of PC3 was significantly inhibited by 39.29%[(63.69%+/-3.69%) vs (102.98%+/-6.84%), P=0.000] after 48 h treatment with lovastatin at its clinically achievable dose of 2 micromol/L. After 72 hours the cell proliferation was inhibited by 44.24% [(52.79%+/-9.88% ) vs (97.03%+/-0.87%), P=0.048]. The cell number was also markedly decreased (4.86x10(5)+/-0.10x10(5)) vs (9.66x10(5)+/-0.10x10(5)), P=0.000] after 72 h treatment at this low concentration of 2 micromol/L. The viability of PC3 cells was significantly decreased 50.12% (56.52%+/-6.40%) vs (106.64%+/-5.27%), P=0.000] and 60.05% (41.99%+/-11.64%) vs (102.94%+/-8.49%), P=0.000] after 48 h and 72 h treatment, respectively. In addition, 2 micromol/L lovastatin induced activation of casepase7 and led the death substrate PARP to cleavage.
  
  
  CONCLUSIONS
  Clinically achievable dose of lovastatin inhibits prostate cancer PC3 cell proliferation and induces PC3 cell apoptosis.
authors: Department of Urology, Peking University First Hospital, Institute of Urology, Peking University, Beijing 100034, China. yanglin2k@126.com
authors: Lin
authors: L
authors: Yang
authors: Ying
authors: Y
authors: Wang
authors: Tian-jing
authors: TJ
authors: Lv
authors: Li-qun
authors: LQ
authors: Zhou
authors: Jie
authors: J
authors: Jin
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D017209:Apoptosis / Q000187:drug effects*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008148:Lovastatin / Q000494:pharmacology*; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*
chemical_list: D000970:Antineoplastic Agents; D008148:Lovastatin